Please login to the form below

Not currently logged in
Email:
Password:

Shire's Q3 net profit doubles

Net profit for Shire recovers from payment to Acceleron and impairment charges relating to the divestment of Daytrana

Shire has recorded a net profit of $192.9m for the third quarter of 2011 – an increase from 2010 of 100 per cent.

Last year, the Ireland-based pharmaceutical company made $96.3m after being hit by payments to Acceleron Pharma and impairment charges related to the divestment of ADHD treatment Daytrana (methylphenidate).

Discounting the one-off charges, as well as other measures specified by the company, net profit was still up, increasing from $220.3m in 2010 to $244.7m in 2011.

This was bolstered by a strong sales performance, with total revenues for Shire increasing 24 per cent to $1.09bn.

Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

Vyvanse made $199.7m, an increase in sales of 32 per cent, while Adderall XR made $149.9m, an increase of 50 per cent.

Angus Russell, CEO of Shire, said: "The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world.

"Overall, we've increased investment in our R&D programmes by 21 per cent compared to Q3 2010, and still generated good earnings growth and strong cashflows."

31st October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics